ArticleFrontiers in pharmacology2025
Pterostilbene mitigates the senescence of human dermal fibroblast cells by enhancing mitochondrial quality.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Photoprotective Potential of a Yeast/Rice Fermentation Filtrate and Sialic Acid in Mitigating UVA-Induced Oxidative Stress and Mitochondrial Dysfunction in Skin Fibroblasts.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pterostilbene (PT), a natural polyphenol found in blueberries and several grape varieties, exhibits pleotropic pharmacological effects. PT reduced the makers of aging caused by either ultraviolet (UV) light exposure or chemical stress in keratinocytes, whereas its potential anti-aging effects and underlying mechanisms in the dermis have not been elucidated. Methods: The anti-senescence effects of PT were investigated in human dermal fibroblasts (HDFs) using models of UVB-induced acute oxidative stress and replicative senescence. Key assays included senescence-associated beta-galactosidase (SA-β-gal) activity, RT-PCR, western blotting, immunofluorescence, live-cell confocal imaging with fluorescent probes, flow cytometry and mitochondrial respiration analysis. A mouse model of UVB-induced skin damage was used to evaluate PT's anti-aging effects in vivo through histopathological examination and western blot analysis. Results: PT treatment mitigated senescence in HDFs, as shown by reduced SA-β-gal activity, p16, and p21, along with increased collagen expression. It restored mitochondrial morphology, MMP, and reduced mitochondrial reactive oxygen species in both senescent models. Furthermore, PT improved mitochondrial basal respiration, ATP production, and maximal respiration. Mechanistically, PT promoted mitophagy, indicated by enhanced TOM20/LC3 colocalization. In vivo, topical PT restored collagen, dermal thickness, and LC3, while reducing p21 levels in UVB-exposed mice. Discussion: Our findings demonstrate that PT delays dermal senescence by enhancing mitochondrial quality via enhancing mitophagy. These results highlight PT as a promising anti-aging agent capable of countering both intrinsic and extrinsic aging in the dermis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.